MTOR and MALT lymphoma: In addition to in vitro data suggesting azithromycin to be a potent mTOR inhibitor in CD4+ T‐cells and thus also displaying immunomodulatory properties,15 different high‐dose long term applications have been shown to be safe in adults and children with cystic fibrosis (10 controlled studies including 632 patients receiving azithromycin over 2‐12 months).16 In view of this, we have hypothesized that azithromycin might have efficacy in MALT lymphoma and have performed a phase II trial to assess the activity of the drug.